IGF::OT::IGF E-SELECTIN/AAV FOR THERAPEUTIC REVERSAL OF LIMB ISCHEMIA

IGF::OT::IGF E-选择素/AAV 用于治疗逆转肢体缺血

• 批准号: 9915772
• 负责人: JILL TINCHER
• 金额: $ 27.6万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-11-15 至 2019-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9915772
• 关键词: Aortic Aneurysm; Area; Bone Marrow; Cell Adhesion Molecules; Cells; Coronary Arteriosclerosis; Disease; Dissection; E-Selectin; Gangrene; Ischemia; Limb structure; Lymphatic Diseases; Lymphatic System; Modeling; Mus; Peripheral arterial disease; Pulmonary Hypertension; Stem cells; Testing; Therapeutic; Thrombosis; Tissues; Universities; Vascular Diseases; Venous; base; extracellular; improved; interest; intracranial artery; medical schools; product development; programs; pulmonary vascular disorder; repaired; stem; tissue repair

The VITA Program will provide support for early-stage translational development of product candidates in the fields of vascular disorders, thrombotic diseases, and pulmonary hypertension. Proposed project areas of interest may include peripheral arterial disease, aortic aneurysms and dissections, pulmonary vascular disorders, venous and arterial thrombosis, thromboembolic disorders, and disorders of the lymphatic system. Not included as specific topics in this program are diseases of the coronary and intracranial arteries.

VITA计划将为血管疾病、血栓性疾病和肺动脉高压领域候选产品的早期转化开发提供支持。拟议的项目领域可能包括外周动脉疾病、主动脉瘤和夹层、肺血管疾病、静脉和动脉血栓形成、血栓栓塞性疾病和淋巴系统疾病。不包括在这个程序的具体主题是冠状动脉和颅内动脉疾病。